In September 2014, Takara Bio Europe AB was formed through the acquisition of Cellectis AB, formerly Cellartis AB, by the Japanese company Takara Bio Inc.
Cellartis was first in the world to bring to the market hepatocytes and cardiomyocytes derived from pluripotent stem cells for use as drug discovery tools and is widely recognised as a premier provider of stem cell derived products and technologies.
Going forward, the stem cell products provided by Takara Bio Europe AB will be marketed under the Cellartis brand name.
Takara Bio Europe AB is focusing on stem cell derived products and services for drug discovery, toxicity testing and applications within regenerative medicine. The company leverages long-standing experience in stem cell handling and scale up together with leading expertise in differentiation of cells into mature and functional human cells.
Takara Bio Europe AB is located in state of the art facilities in Göteborg, Sweden. The laboratories are prepared to meet the EU and US guidelines for current Good Manufacturing Practice (cGMP).